Girish Wadhwa - Mega Lifesciences Managing Director of Myanmar
| MEGA Stock | THB 34.75 0.25 0.71% |
Managing Director
Girish Wadhwa is Managing Director of Myanmar of Mega Lifesciences Public since 1998.
| Age | 53 |
| Tenure | 26 years |
| Phone | 66 2 769 4222 |
| Web | https://www.megawecare.com |
Mega Lifesciences Management Efficiency
The company has return on total asset (ROA) of 0.1239 % which means that it generated a profit of $0.1239 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.2915 %, meaning that it generated $0.2915 on every $100 dollars invested by stockholders. Mega Lifesciences' management efficiency ratios could be used to measure how well Mega Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Found 1 records | MANAGING DIRECTOR Age | ||
| Khunawut Thumpomkul | Home Product Center | 66 | |
Management Performance
| Return On Equity | 0.29 | |||
| Return On Asset | 0.12 |
Mega Lifesciences Public Leadership Team
Elected by the shareholders, the Mega Lifesciences' board of directors comprises two types of representatives: Mega Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Mega. The board's role is to monitor Mega Lifesciences' management team and ensure that shareholders' interests are well served. Mega Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Mega Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Duangnapa Tongsiri, Pres Thailand | ||
| Apichai Chanjarusiri, Manufacturing Thailand | ||
| Vivek Dhawan, CEO, Chief Coach, Director and Member of Remuneration and Nomination Committee | ||
| Manoj Gurbuxani, Deputy Officer | ||
| Thomas Abraham, CFO and Director | ||
| Deepak Panjwani, Chief Officer | ||
| Paramjit Sawhney, President of International | ||
| Sujintana Boonworapat, Co Sec | ||
| Girish Wadhwa, Managing Director of Myanmar |
Mega Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Mega Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.29 | |||
| Return On Asset | 0.12 | |||
| Profit Margin | 0.15 % | |||
| Operating Margin | 0.17 % | |||
| Current Valuation | 38.59 B | |||
| Shares Outstanding | 871.87 M | |||
| Shares Owned By Insiders | 60.85 % | |||
| Shares Owned By Institutions | 7.67 % | |||
| Price To Book | 4.70 X | |||
| Price To Sales | 2.68 X |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Mega Stock
Mega Lifesciences financial ratios help investors to determine whether Mega Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Mega with respect to the benefits of owning Mega Lifesciences security.